Not Signed In - Return On Investment For Pediatric Exclusivity Program Varies Widely For Pharmaceutical Companies
Fri, 09 Feb 2007 03:00 PM EST
... The economic return for a program designed to encourage drug manufacturers to conduct more pediatric clinical trials by granting extensions of patent protection or marketing exclusivity generates lucrative returns for blockbuster products and produces more modest returns on investment for many others, according to a study in the February 7 issue of JAMA.In 1997, Congress authorized the U.S. [click link for full article] ...
Related Topics
- Children's Health
- Pediatric Care
- Pediatric Aids
- Mental impairment (varies, usually minimal)
- Relapse (return) of infection
- Return of bleeding after treatment
- Return (recurrence) of infection
- Autoimmune Disorders
- Total anomalous pulmonary venous return
- Return of the infection (relapse or disease recurrence)
- Didanosine Pediatric Oral Solution
- Drug Information
- Anesthesia
- Adolescents/Adolescence
- Health psychology
- Wellness
- Exercise for Seniors
- Emergency Medicine
- Wellness and Lifestyle
- Incarceration
email this page
print this page
bookmark this page
feedback on this page
